Action Biotech believes in the substantial future potential of stem cell treatments for many serious health conditions.   We are venture capitalists who invest strategically in small companies that have promising stem cell capabilities. 

Some of the Californian stem cell companies in which we have invested are beginning to show promising results in fields such as somatic cell nuclear transfer, or "personalized stem cell lines" which contain the personal DNA of the patient, thereby eliminating the body's normal immune system rejection, which is one of the limitations of current stem cell treatments. 

However, we recognize that this field is a long road, with both progress and set-backs.  We believe the field will move ahead more rapidly as the $3 billion from California's much-delayed "Prop 71" stem cell funding bill begins to become available to private companies from 2009 onwards.